• Eur. J. Heart Fail. · Nov 2020

    Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.

    • Radek Pudil, Christian Mueller, Jelena Čelutkienė, Peter A Henriksen, Dan Lenihan, Susan Dent, Ana Barac, Susanna Stanway, Javid Moslehi, Thomas M Suter, Bonnie Ky, Martin Štěrba, Daniela Cardinale, Alain Cohen-Solal, Carlo Gabriele Tocchetti, Dimitrios Farmakis, Jutta Bergler-Klein, Markus S Anker, Stephan Von Haehling, Yury Belenkov, Zaza Iakobishvili, Christoph Maack, Fortunato Ciardiello, Frank Ruschitzka, Coats Andrew J S AJS University of Warwick, Warwick, UK. Pharmacology Centre of Clinical and Experimenta, Petar Seferovic, Mitja Lainscak, Massimo F Piepoli, Ovidiu Chioncel, Jereon Bax, Jean-Sebastien Hulot, Hadi Skouri, Eva Simona Hägler-Laube, Riccardo Asteggiano, Teresa Lopez Fernandez, Rudolf A de Boer, and Alexander R Lyon.
    • 1st Department Medicine - Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove, Prague, Czech Republic.
    • Eur. J. Heart Fail. 2020 Nov 1; 22 (11): 1966-1983.

    AbstractSerum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed.© 2020 European Society of Cardiology.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…